Details for New Drug Application (NDA): 204696
✉ Email this page to a colleague
NDA 204696 describes LINEZOLID, which is a drug marketed by Hetero Labs, Hikma, Eugia Pharma, Fresenius Kabi Usa, Hospira, Hq Spclt Pharma, Mylan Labs Ltd, Nang Kuang Pharm Co, Sagent Pharms Inc, Sandoz, Teva Pharms, Alembic, Alkem Labs Ltd, Amneal Pharms, Chartwell Rx, Gate Pharms, Glenmark Speclt, Hetero Labs Ltd V, Macleods Pharms Ltd, Novel Labs Inc, Rising, Teva Pharms Usa, and Zydus Pharms, and is included in twenty-five NDAs. It is available from twenty-two suppliers. Additional details are available on the LINEZOLID profile page.
The generic ingredient in LINEZOLID is linezolid. There are twenty-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the linezolid profile page.
The generic ingredient in LINEZOLID is linezolid. There are twenty-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the linezolid profile page.
Summary for 204696
| Tradename: | LINEZOLID |
| Applicant: | Sagent Pharms Inc |
| Ingredient: | linezolid |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 204696
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 200MG/100ML (2MG/ML) | ||||
| Approval Date: | Mar 2, 2017 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 600MG/300ML (2MG/ML) | ||||
| Approval Date: | Mar 2, 2017 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
